Immunotech Laboratories, Inc. (IMMB)
Immunotech Laboratories, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Monrovia, CA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $114,993. On trailing twelve-month figures it carries a trailing P/E of -0.22, a net margin of 0.0%. Its beta of -5.14 implies it has historically moved less than the broad market.
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Enzolytics, Inc.
Immunotech Laboratories, Inc. is most often compared with the following Healthcare names: